Solara Active Pharma Sciences Ltd (BOM:541540) Q1 2027 Earnings Call Highlights: Strong Revenue ...
NiveshIQ
NSE: ALIVUS · Healthcare
Alivus Life Sciences Ltd.
₹1,119.60▲ ₹14.90 (+1.35%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ALIVUS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alivus Life Sciences Ltd.
Alivus Life Sciences Limited is a leading Indian pharmaceutical company that develops, manufactures, and markets active pharmaceutical ingredients (APIs) globally. The company offers a diverse portfolio of APIs across various therapeutic areas, including cardiovascular disease, central nervous system disorders, and oncology. Alivus Life Sciences also provides contract development and manufacturing services to multinational corporations and specialty companies. The company has a strong presence in international markets, including Japan, Europe, North and Latin America, and exports its products. With a revenue of ₹2552 Cr and net income of ₹564 Cr, Alivus Life Sciences has demonstrated its financial stability and growth potential. The company's strategic outlook and high-growth future prospe
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,185 Cr +6.70% | ₹2,340 Cr +7.10% | ₹2,552 Cr +9.10% |
| EBITDA Margin | 31.41% | 31.53% | 33.61% |
| Net Profit | ₹470.89 Cr +0.80% | ₹485.63 Cr +3.10% | ₹564.48 Cr +16.20% |
| EPS | ₹38.43 | ₹18.96 | ₹45.99 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Alivus Life Sciences to Host Q1 Earnings Call on July 31
Alivus Life Sciences to host Q1 FY2026-27 earnings call on July 31
🔒
+ 3 more stories about Alivus Life Sciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹689 Cr, PAT ₹163 Cr, EPS ₹13.23, EBITDA margin 34.4%. Growth context: revenue YoY +14.4%, PAT YoY +14.7%, revenue QoQ +2.4%, PAT QoQ +8.3%. Street verdict: strong miss, revenue surprise -0.2%, PAT surprise -37.7%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline will be the key drivers for Ali...
FY26 (last completed FY): revenue ₹2, 552 Cr, PAT ₹564 Cr, EBITDA margin 33.6%, EPS ₹45.99. Year-on-year: revenue YoY +9...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ALIVUS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ALIVUS alongside your other holdings
Unlock full ALIVUS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alivus Life Sciences Ltd.?
NiveshIQ detects active intelligence signals for Alivus Life Sciences Ltd. (ALIVUS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alivus Life Sciences Ltd.?
Alivus Life Sciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,378,329.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.